KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance :: KORU Medical Systems (KRMD)

About this update from Koru Medical Systems, Inc.

KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance August 05, 2026 4:05 pm EDT Download as PDF MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full year 2026. Second Quarter 2026 and Recent Highlights Net revenues grew 18% over the prior year period to $12.0 million Gross profit grew 20% over the prior year period to $7.8 million, with gross margin of 65.1% Net income improved 222% over the prior year period to $0.25 million Acquired a connected monitoring technology asset, representing strategic investment to potentially enhance and differentiate the KORU platform through valuable real-time data insights into patient usage Strategically shifting U.S. oncology market entry to focus on alternative higher volume molecules and withdrawing 510(k) application for the FreedomEDGE® with Phesgo® in the U.S. Entered into a multi-year supply agreement to support operational strategy, product assurance, and long-term gross margin expansion Refining full year 2026 guidance to include: Revenue of $47.5 - $48.5 million, gross margin of 62% - 64%, positive adjusted EBITDA, and year end cash balance of greater than $7.5 million "We delivered record revenue, improved gross margins and generated positive net income for the quarter, all of which demonstrate our ability to drive durable and profitable growth in the subcutaneous drug delivery market," said Adam Kalbermatten, President and CEO of KORU Medical. "We also acquired a technology asset, representing a strategic investment in connected monitoring potential to further enhance the patient experience and differentiate KORU's value proposition to our partners. "Looking ahead for the remainder of 2026, we expect our international core growth to moderate as we navigate regional launch dynamics in specific European markets converting to pre-filled syringes. We remain confident in the size of our international opportunity and view capturing this business only as a matter of timing. Additionally, we have withdrawn our Phesgo® 5...

View stock analysis, news, and events for Koru Medical Systems, Inc.